Sufentanil transdermal - tesa Labtec

Drug Profile

Sufentanil transdermal - tesa Labtec

Alternative Names: Sufentanil TDS

Latest Information Update: 09 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Labtec
  • Developer hameln rds; tesa Labtec
  • Class Amides; General anaesthetics; Opioid analgesics; Piperidines; Small molecules; Thiophenes
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer pain; Pain

Most Recent Events

  • 08 Mar 2017 Discontinued - Phase-I for Pain in Germany before March 2017 (Transdermal)
  • 08 Mar 2017 Discontinued - Phase-II for Cancer pain in Slovakia before March 2017 (Transdermal)
  • 27 Jul 2015 No recent reports on development identified - Phase-I for Pain in Germany (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top